MAOA and Parkinson disease: Simple and fused chromones’ derivatives showed potential in the design of multitarget-directed ligands (MTDLs) for treating neurodegenerative disorders, i.e., Alzheimer’s (AD) or Parkinson’s disease (PD), as inhibitors of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), monoamine oxidases A and B (MAO A and B) and amyloid beta (Aβ) plaque formation and aggregation [2,3].